Kisqali: Interim analysis data from P3 NATALEE trial (NCT03701334) for adjuvant HR+, HER2(-) breast cancer in H1 2021 (Novartis) - Jan 29, 2020 - Q4 and FY 2019 Results: Final data from P3 NATALEE trial for adjuvant HR+, HER2(-) breast cancer in 2026
P3 data
|